53 related articles for article (PubMed ID: 38690600)
21. Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.
Badia E; Oliva J; Balaguer P; Cavaillès V
Curr Med Chem; 2007; 14(28):3035-45. PubMed ID: 18220739
[TBL] [Abstract][Full Text] [Related]
22. Hormonal modulation in the treatment of breast cancer.
Adelson K; Germain D; Raptis G; Biran N
Endocrinol Metab Clin North Am; 2011 Sep; 40(3):519-32, viii. PubMed ID: 21889718
[TBL] [Abstract][Full Text] [Related]
23. Overcoming Endocrine Resistance in Breast Cancer.
Hanker AB; Sudhan DR; Arteaga CL
Cancer Cell; 2020 Apr; 37(4):496-513. PubMed ID: 32289273
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.
Zilli M; Grassadonia A; Tinari N; Di Giacobbe A; Gildetti S; Giampietro J; Natoli C; Iacobelli S;
Biochim Biophys Acta; 2009 Jan; 1795(1):62-81. PubMed ID: 18804516
[TBL] [Abstract][Full Text] [Related]
25. The interaction between ER and NFκB in resistance to endocrine therapy.
Sas L; Lardon F; Vermeulen PB; Hauspy J; Van Dam P; Pauwels P; Dirix LY; Van Laere SJ
Breast Cancer Res; 2012 Aug; 14(4):212. PubMed ID: 22963717
[TBL] [Abstract][Full Text] [Related]
26. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer.
Toska E
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189097. PubMed ID: 38518961
[TBL] [Abstract][Full Text] [Related]
28. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
Kulkoyluoglu E; Madak-Erdogan Z
Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
[TBL] [Abstract][Full Text] [Related]
29. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Nagaraj G; Ma C
Breast Cancer Res Treat; 2015 Apr; 150(2):231-42. PubMed ID: 25762475
[TBL] [Abstract][Full Text] [Related]
30. Endocrine resistance: what do we know?
Miller TW
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714450
[TBL] [Abstract][Full Text] [Related]
31. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.
Kurebayashi J
Breast Cancer; 2003; 10(2):112-9. PubMed ID: 12736563
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
33. Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.
Mancuso MR; Massarweh SA
Curr Probl Cancer; 2016; 40(2-4):95-105. PubMed ID: 27839747
[TBL] [Abstract][Full Text] [Related]
34. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
Giuliano M; Schifp R; Osborne CK; Trivedi MV
Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
[TBL] [Abstract][Full Text] [Related]
35. Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.
Li Y; Kong X; Xuan L; Wang Z; Huang YH
J Cell Mol Med; 2021 Nov; 25(22):10327-10348. PubMed ID: 34651424
[TBL] [Abstract][Full Text] [Related]
36. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
AlFakeeh A; Brezden-Masley C
Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
[TBL] [Abstract][Full Text] [Related]
37. Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer.
Reinert T; de Paula B; Shafaee MN; Souza PH; Ellis MJ; Bines J
Chin Clin Oncol; 2018 Jun; 7(3):25. PubMed ID: 30056727
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of endocrine therapy resistance in breast cancer.
Rasha F; Sharma M; Pruitt K
Mol Cell Endocrinol; 2021 Jul; 532():111322. PubMed ID: 34000350
[TBL] [Abstract][Full Text] [Related]
39. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
40. New agents for endocrine resistance in breast cancer.
Maurer C; Martel S; Zardavas D; Ignatiadis M
Breast; 2017 Aug; 34():1-11. PubMed ID: 28448864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
